Working… Menu

A Study to Investigate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Efficacy of Risdiplam (RO7034067) in Type 2 and 3 Spinal Muscular Atrophy (SMA) Participants (SUNFISH)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT02908685
Recruitment Status : Active, not recruiting
First Posted : September 21, 2016
Last Update Posted : July 22, 2020
Information provided by (Responsible Party):
Hoffmann-La Roche

Results Submitted - Not Posted on
Results information has been submitted to by the sponsor or investigator, but is not yet publicly available (or "posted") on The submitted information may not be available if it is pending Quality Control (QC) Review by the National Library of Medicine (NLM) or if issues identified during QC review are being addressed or corrected by the sponsor or investigator. NLM's limited QC review assesses for apparent errors, deficiencies, or inconsistencies. NLM staff do not verify the scientific validity or relevance of the submitted information.
Recruitment Status : Active, not recruiting
Actual Primary Completion Date : September 6, 2019
Estimated Study Completion Date : September 2, 2023
Submission Cycle Results Submitted to Results Returned after Quality Control Review
1 August 27, 2020
September 18, 2020
2 November 17, 2020
December 11, 2020
3 January 19, 2021
February 9, 2021
4 April 19, 2021